Search

Your search keyword '"Adelstein, David J."' showing total 3 results
Start Over Author "Adelstein, David J." Publication Type Electronic Resources
3 results on '"Adelstein, David J."'

1. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.

Author

Gillison, Maura L, Gillison, Maura L, Trotti, Andy M, Harris, Jonathan, Eisbruch, Avraham, Harari, Paul M, Adelstein, David J, Jordan, Richard CK, Zhao, Weiqiang, Sturgis, Erich M, Burtness, Barbara, Ridge, John A, Ringash, Jolie, Galvin, James, Yao, Min, Koyfman, Shlomo A, Blakaj, Dukagjin M, Razaq, Mohammed A, Colevas, A Dimitrios, Beitler, Jonathan J, Jones, Christopher U, Dunlap, Neal E, Seaward, Samantha A, Spencer, Sharon, Galloway, Thomas J, Phan, Jack, Dignam, James J, Le, Quynh Thu, Gillison, Maura L, Gillison, Maura L, Trotti, Andy M, Harris, Jonathan, Eisbruch, Avraham, Harari, Paul M, Adelstein, David J, Jordan, Richard CK, Zhao, Weiqiang, Sturgis, Erich M, Burtness, Barbara, Ridge, John A, Ringash, Jolie, Galvin, James, Yao, Min, Koyfman, Shlomo A, Blakaj, Dukagjin M, Razaq, Mohammed A, Colevas, A Dimitrios, Beitler, Jonathan J, Jones, Christopher U, Dunlap, Neal E, Seaward, Samantha A, Spencer, Sharon, Galloway, Thomas J, Phan, Jack, Dignam, James J, and Le, Quynh Thu

Abstract

BackgroundPatients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma have high survival when treated with radiotherapy plus cisplatin. Whether replacement of cisplatin with cetuximab-an antibody against the epidermal growth factor receptor-can preserve high survival and reduce treatment toxicity is unknown. We investigated whether cetuximab would maintain a high proportion of patient survival and reduce acute and late toxicity.MethodsRTOG 1016 was a randomised, multicentre, non-inferiority trial at 182 health-care centres in the USA and Canada. Eligibility criteria included histologically confirmed HPV-positive oropharyngeal carcinoma; American Joint Committee on Cancer 7th edition clinical categories T1-T2, N2a-N3 M0 or T3-T4, N0-N3 M0; Zubrod performance status 0 or 1; age at least 18 years; and adequate bone marrow, hepatic, and renal function. We randomly assigned patients (1:1) to receive either radiotherapy plus cetuximab or radiotherapy plus cisplatin. Randomisation was balanced by using randomly permuted blocks, and patients were stratified by T category (T1-T2 vs T3-T4), N category (N0-N2a vs N2b-N3), Zubrod performance status (0 vs 1), and tobacco smoking history (≤10 pack-years vs >10 pack-years). Patients were assigned to receive either intravenous cetuximab at a loading dose of 400 mg/m2 5-7 days before radiotherapy initiation, followed by cetuximab 250 mg/m2 weekly for seven doses (total 2150 mg/m2), or cisplatin 100 mg/m2 on days 1 and 22 of radiotherapy (total 200 mg/m2). All patients received accelerated intensity-modulated radiotherapy delivered at 70 Gy in 35 fractions over 6 weeks at six fractions per week (with two fractions given on one day, at least 6 h apart). The primary endpoint was overall survival, defined as time from randomisation to death from any cause, with non-inferiority margin 1·45. Primary analysis was based on the modified intention-to-treat approach, whereby all patients meeting eligibility crite

Published
2019

2. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Author

Bauman, Julie E, Bauman, Julie E, Cohen, Ezra, Ferris, Robert L, Adelstein, David J, Brizel, David M, Ridge, John A, O'Sullivan, Brian, Burtness, Barbara A, Butterfield, Lisa H, Carson, William E, Disis, Mary L, Fox, Bernard A, Gajewski, Thomas F, Gillison, Maura L, Hodge, James W, Le, Quynh-Thu, Raben, David, Strome, Scott E, Lynn, Jean, Malik, Shakun, Bauman, Julie E, Bauman, Julie E, Cohen, Ezra, Ferris, Robert L, Adelstein, David J, Brizel, David M, Ridge, John A, O'Sullivan, Brian, Burtness, Barbara A, Butterfield, Lisa H, Carson, William E, Disis, Mary L, Fox, Bernard A, Gajewski, Thomas F, Gillison, Maura L, Hodge, James W, Le, Quynh-Thu, Raben, David, Strome, Scott E, Lynn, Jean, and Malik, Shakun

Abstract

Recent advances have permitted successful therapeutic targeting of the immune system in head and neck squamous cell carcinoma (HNSCC). These new immunotherapeutic targets and agents are being rapidly adopted by the oncologic community and hold considerable promise. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issue of how to further investigate the use of immunotherapy in patients with HNSCC. The goals of the meeting were to consider phase 2 or 3 trial designs primarily in 3 different patient populations: those with previously untreated, human papillomavirus-initiated oropharyngeal cancers; those with previously untreated, human papillomavirus-negative HNSCC; and those with recurrent/metastatic HNSCC. In addition, a separate committee was formed to develop integrative biomarkers for the clinical trials. The meeting started with an overview of key immune components and principles related to HNSCC, including immunosurveillance and immune escape. Four clinical trial concepts were developed at the meeting integrating different immunotherapies with existing standards of care. These designs were presented for implementation by the head and neck committees of the National Cancer Institute-funded National Clinical Trials Network. This article summarizes the proceedings of this Clinical Trials Planning Meeting, the purpose of which was to facilitate the rigorous development and design of randomized phase 2 and 3 immunotherapeutic trials in patients with HNSCC. Although reviews usually are published immediately after the meeting is held, this report is unique because there are now tangible clinical trial designs that have been funded and put into practice and the studies are being activated to accrual. Cancer 2017;123:1259-1271. © 2016 American Cancer Society.

Published
2017

3. Transoral resection of pharyngeal cancer: Summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6???7, 2011, Arlington, Virginia

Author

University of Michigan, Ann Arbor, Michigan, Fox Chase Cancer Center, Philadelphia, Pennsylvania, Johns Hopkins University School of Medicine, Baltimore, Maryland, University of Pennsylvania, Philadelphia, Pennsylvania, Georgia Cancer Coalition Distinguished Scholar, Winship Cancer Institute, Emory University, Atlanta, Georgia, Mount Sinai School of Medicine, New York, New York, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada, Washington University School of Medicine, Siteman Cancer Center, St. Louis, Missouri, University of Texas MD Anderson Cancer Center, Houston, Texas, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, Duke Cancer Institute, Durham, North Carolina, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, National Cancer Institute, Bethesda, Maryland, Ohio State University Comprehensive Cancer Center, Columbus, Ohio, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, University of Minnesota, Minneapolis, Minnesota, Dana???Farber Cancer Institute, Boston, Massachusetts, Fred Hutchinson Cancer Research Center, Seattle, Washington, Mayo Clinic, Rochester, Minnesota, Henry Ford Hospital, Detroit, Michigan, University of Pittsburgh, Pittsburgh, Pennsylvania, Adelstein, David J., Ridge, John A., Brizel, David M., Holsinger, F. Christopher, Haughey, Bruce H., O'Sullivan, Brian, Genden, Eric M., Beitler, Jonathan J., Weinstein, Gregory S., Quon, Harry, Chepeha, Douglas B., Ferris, Robert L., Weber, Randal S., Movsas, Benjamin, Waldron, John, Lowe, Val, Ramsey, Scott, Manola, Judith, Yueh, Bevan, Carey, Thomas E., Bekelman, Justin E., Konski, Andre A., Moore, Eric, Forastiere, Arlene, Schuller, David E., Lynn, Jean, Ullmann, Claudio Dansky, University of Michigan, Ann Arbor, Michigan, Fox Chase Cancer Center, Philadelphia, Pennsylvania, Johns Hopkins University School of Medicine, Baltimore, Maryland, University of Pennsylvania, Philadelphia, Pennsylvania, Georgia Cancer Coalition Distinguished Scholar, Winship Cancer Institute, Emory University, Atlanta, Georgia, Mount Sinai School of Medicine, New York, New York, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada, Washington University School of Medicine, Siteman Cancer Center, St. Louis, Missouri, University of Texas MD Anderson Cancer Center, Houston, Texas, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, Duke Cancer Institute, Durham, North Carolina, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, National Cancer Institute, Bethesda, Maryland, Ohio State University Comprehensive Cancer Center, Columbus, Ohio, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, University of Minnesota, Minneapolis, Minnesota, Dana???Farber Cancer Institute, Boston, Massachusetts, Fred Hutchinson Cancer Research Center, Seattle, Washington, Mayo Clinic, Rochester, Minnesota, Henry Ford Hospital, Detroit, Michigan, University of Pittsburgh, Pittsburgh, Pennsylvania, Adelstein, David J., Ridge, John A., Brizel, David M., Holsinger, F. Christopher, Haughey, Bruce H., O'Sullivan, Brian, Genden, Eric M., Beitler, Jonathan J., Weinstein, Gregory S., Quon, Harry, Chepeha, Douglas B., Ferris, Robert L., Weber, Randal S., Movsas, Benjamin, Waldron, John, Lowe, Val, Ramsey, Scott, Manola, Judith, Yueh, Bevan, Carey, Thomas E., Bekelman, Justin E., Konski, Andre A., Moore, Eric, Forastiere, Arlene, Schuller, David E., Lynn, Jean, and Ullmann, Claudio Dansky

Abstract

Recent advances now permit resection of many pharyngeal tumors through the open mouth, an approach that can greatly reduce the morbidity of surgical exposure. These transoral techniques are being rapidly adopted by the surgical community and hold considerable promise. On November 6???7, 2011, the National Cancer Institute sponsored a Clinical Trials Planning Meeting to address how to further investigate the use of transoral surgery, both in the good prognosis human papillomavirus (HPV)???initiated oropharyngeal cancers, and in those with HPV???unrelated disease. The proceedings of this meeting are summarized. ?? 2012 Wiley Periodicals, Inc. Head Neck, 2012

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results